For decades, most African nations have relied heavily on imported medications to meet their healthcare needs. In this analysis, Dr. Arnaud Kaboré, a pharmacist and engineer with deep industry expertise, outlines a strategic roadmap for policymakers to achieve pharmaceutical sovereignty by 2045.
The hidden risks of pharmaceutical dependence
Despite progress in some areas, fewer than five African countries currently operate manufacturing facilities capable of supplying beyond their borders. This leaves the continent importing 94% of its medicines at an annual cost exceeding $18 billion—figures projected to surge past $30 billion by 2030. Beyond economic strain, this dependency exposes Africa’s healthcare systems to severe vulnerabilities.
According to recent assessments, over 70% of public health facilities across the continent face at least one critical drug shortage each quarter. Is it sustainable for the health of 1.4 billion Africans to hinge entirely on decisions made outside the continent? The Covid-19 pandemic laid bare these risks, with recurring shortages of essential drugs like amoxicillin, insulin, and anesthetics, alongside chronic inaccessibility to cancer treatments and advanced therapies. The human cost is staggering: untreated illnesses, price surges during shortages, and stalled public health programs. Yet Africa possesses untapped potential:
- A rapidly expanding pharmaceutical market projected to exceed $70 billion by 2030;
- Exceptional biodiversity with over 5,400 documented medicinal plants, some already integrated into official treatment protocols;
- A strengthening regulatory framework through the African Medicines Agency (AMA), now endorsed by 27 countries;
- Bold political commitments from nations like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa, all launching ambitious local production initiatives.
Building Africa’s pharmaceutical future: a sustainable path forward
One critical misstep has been attempting to replicate the models of multinational pharmaceutical giants without establishing foundational capabilities or control over the value chain. Industrialization cannot be achieved through imported equipment alone—it requires deliberate investment in human capital, technical expertise, and local industrial assets. Without these pillars, local production often becomes more expensive than imports, perpetuating dependency on foreign raw materials, technologies, and expertise.
True pharmaceutical sovereignty demands rigor, long-term vision, and a strategy rooted in Africa’s unique strengths: a growing market, medicinal biodiversity, regulatory momentum, and political will. Dr. Kaboré’s roadmap calls for policymakers to prioritize sustainable industrialization as part of a broader economic transformation. The goal is clear: produce locally to heal locally, and in time, extend these capabilities to the world.
Dr. Arnaud Kaboré
Pharmacist and Healthcare Executive
